Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

7/27/2015 HEMISPHERX BIOPHARMA TO HOST STOCKHOLDER OPEN HOUSE AT MANUFACTURING AND RESEARCH FACILITY IN NEW JERSEY

7/23/2015 Hemispherx Biopharma Announces Final Approval of Securities Class Action Settlement

7/15/2015 Hemispherx Biopharma Europe N.V./S.A. Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection® for Treatment of Middle East Respiratory Syndrome (MERS)

6/25/2015 Hemispherx Receives the European Patent Office Examining Division’s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen® Formulations

6/4/2015 Hemispherx Biopharma Announces Preliminary Approval of Securities Class Action Settlement

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com